From our friends at the IBTA! This is the last issue Denis will contribute to as he is retiring. He did a great job for years and I am sure Kathy will do a great job also! Happy Retirement Denis!
This newsletter mentions 2 very important articles: One showing that Gliolan is better than intraoperative MRI. Gliolan is a dye that makes the tumor light up during surgery. It is approved in Europe but not available yet in the USA.
The other article is on the CTLA-4 blockade. Worth reading!
NovoTTF-100A alternating electric fields therapy for recurrent glioblastoma: An analysis of patient registry data. The first 457 patient with recurrent gbms who used the Novocure NovoTTF-100a therapy after it was FDA approved were analyzed to see how they did. This is for people outside of the trials. Results were much better than the large trial that resulted in FDA approval.
There are 2 trials going on novocure device. One for newly diagnosed gbm and one for recurrent gbm. It is also available by prescription at over 100 major brain tumor centers (The advantage of entering the trials are the costs.)
